Search results
Showing 6256 to 6270 of 7680 results
This guidance has been updated and replaced by NICE interventional procedures guidance 740.
Endovascular aneurysm sealing for abdominal aortic aneurysm (IPG547)
March 2019: We have withdrawn the guidance because the CE mark for the Nellix Endovascular Aneurysm Sealing (EVAS) System has been withdrawn. Endologix is recalling unused stock. The MHRA recommends enhanced patient surveillance (see MDA/2019/002) because of a high risk of the graft failing beyond 2 years after implantation.
Hysteroscopic sterilisation by insertion of intrafallopian implants (IPG587)
October 2017: The device used in this procedure (Essure) no longer has a CE mark. The CE mark is necessary for medical devices to be used in EU countries. Therefore NICE has decided to suspend its guidance. NICE would consider whether to issue new guidance on “Hysteroscopic sterilisation by insertion of intrafallopian implants” should evidence including an appropriately CE marked device become available.
Extracorporeal carbon dioxide removal for acute respiratory failure (IPG564)
This guidance has been updated and replaced by NICE interventional procedure guidance 776.
This guidance has been updated and replaced by NICE guideline CG44.
Biodegradable subacromial spacer insertion for rotator cuff tears (IPG558)
This guidance has been updated and replaced by NICE interventional procedures guidance IPG775.
This guidance has been updated and replaced by NICE interventional procedures guidance 723.
Irreversible electroporation for treating prostate cancer (IPG572)
This guidance has been updated and replaced by NICE interventional procedures guidance 768.
October 2018: The device used in this procedure (CyPass) has been withdrawn by the manufacturer Alcon, because of concerns about its long-term safety. Further details can be found in the Voluntary Field Safety Notice issued by Alcon. Surgeons are advised not to implant this device, to return any unused devices to Alcon and to consider reviewing any patients who have already been implanted with CyPass. Therefore NICE has decided to withdraw its guidance. NICE would consider whether to issue new guidance on ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma should evidence using an appropriately CE marked device become available.
This guidance has been withdrawn as the use of this procedure is now covered in the NICE guideline on heavy menstrual bleeding (CG44). NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme.
Endovascular stent insertion for intracranial atherosclerotic disease (IPG233)
This guidance has been updated and replaced by NICE interventional procedure guidance 429.
Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction (IPG237)
This guidance has been updated and replaced by NICE Interventional procedure guidance 436.
Laparoscopic radical hysterectomy for early stage cervical cancer (IPG24)
This guidance has been updated and replaced by NICE interventional procedure guidance 338.
Circumferential epithelial radiofrequency ablation for Barrett's oesophagus (IPG244)
This guidance has been updated and replaced by NICE interventional procedure guidance 344.
Arteriovenous extracorporeal membrane carbon dioxide removal (IPG250)
This guidance has been updated and replaced by NICE interventional procedure guidance 428.